Iterum Therapeutics Shares Latest Business Developments

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Nov 24 2025

0mins

Source: Globenewswire

Recent Developments: Iterum Therapeutics announced that its antibiotic ORLYNVAH™ is now available through McKesson, allowing physicians to procure it directly, and that its sulopenem susceptibility disc has received FDA clearance for use in microbiology laboratories.
Product Information: ORLYNVAH™ is an oral penem antibiotic effective against multi-drug resistant bacteria, specifically targeting uncomplicated urinary tract infections in women with limited treatment options.
Company Focus: Iterum is dedicated to developing next-generation antibiotics to combat multi-drug resistant pathogens, with a focus on improving treatment outcomes for serious infections.
Forward-Looking Statements: The company cautions that its future plans and market potential are subject to various risks and uncertainties that could significantly impact actual results compared to expectations.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free